Coadministration of Nefazodone and Desipramine: A pharmacokinetic interaction study

Journal of the Pakistan Medical Association

Volumn 57, Issue 5, 2007, Pages 230-235

  Khan, Ahsan Y ^a   Preskorn, Sheldon H ^a   Horst, W Dale ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROPHENYLPIPERAZINE; 2 HYDROXYDESIPRAMINE; DESIPRAMINE; DRUG METABOLITE; HYDROXYNEFAZODONE; NEFAZODONE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; TRIAZOLE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MALE; NORMAL HUMAN; STATISTICAL SIGNIFICANCE; TACHYCARDIA; ADOLESCENT; DRUG INTERACTION; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DESIPRAMINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIAZOLES;

EID: 34548833078     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Eison A, Eison M, Torrente J, Wight RH, Yocca FD, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-5.
2. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Science 1995;57:373-80.
3. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56:3-11.
4. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
5. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399-408.
6. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-6.
7. Dockens RC, Rapoport D, Roberts D, Greene DS, Barbhaiya RH. Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 1995;40:598-601.
8. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996;42:573-81.
9. Franc JE. A robotic HPLC procedure for metabolizer phenotyping using dextromethorphan in human urine. 1989;Bristol-Meyers Squibb Co., PRI, Report No. FRAN-JE-21140:
10. Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr Biomed Appl 1991;570:129-38.
11. Nielson KK, Brosen K. High-performance liquid chromatography of Imipramine and six metabolites in human plasma and urine. J Chromatography 1993;612:87-94.
12. Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker, Inc., 1982; pp. 409-17.
13. Riegelman S, Collier P. An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption. J Pharmacokinet Biopharm 1980;8:509-34.
14. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation. Br J Clin Pharmacol 1996;41:339-43.
15. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
16. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450 2D6 activity in human liver microsomes. Br J Clin Pharmacol 1991;32:5.
17. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update (editorial). J Clin Psychopharmacol 1996;16:197-201.
18. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine, J Clin Psychopharmacol 1994;14:90-8.
19. Brosen K, Hansen JG, Neilsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.